Skip to main content
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. — Investor Relations & Filings

Ticker · VVOS ISIN · US92859E1082 US Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2024-11-27 Director's Dealing
Country US United States of America
Listing US VVOS

About Vivos Therapeutics, Inc.

https://vivos.com/

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company's core offering is The Vivos System, a non-surgical treatment that uses proprietary oral appliances. These devices are designed to address underlying dentofacial abnormalities that can restrict the airway. The treatment protocol aims to promote the natural growth and development of the jaw and airway in both adult and pediatric patients. Vivos provides its technology and training to a network of licensed dentists and medical professionals who deliver the therapy.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-11-27 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-14 English
Earnings Release 2024
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Vivos Therapeutics, Inc. It announces the issuance of a press release with financial results for the third quarter ended September 30, 2024. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the document itself does not contain detailed financial statements or substantive financial data. The length is 4269 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release itself. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly financial results and includes a press release with key highlights, but does not contain the full detailed report or financial statements that would qualify as an Interim/Quarterly Report (IR).
2024-11-14 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q3 2024
2024-11-14 English
SC 13G/A
Major Shareholding Notification
2024-11-14 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or supplemental proxy materials related to the Annual Meeting of Stockholders. It includes information about proposals to be voted on, such as election of directors, approval of equity incentive plans, and ratification of auditors. The document is titled 'Supplemental Proxy Materials' and is clearly intended to solicit votes from shareholders for the upcoming annual meeting. It does not contain financial statements or detailed financial results, nor is it an announcement of a report publication. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI).
2024-11-06 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.